Search

Your search keyword '"Sokol, Lubomir"' showing total 1,509 results
Start Over Author "Sokol, Lubomir"
1,509 results on '"Sokol, Lubomir"'

1. Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma

Author

Witzig, Thomas, Sokol, Lubomir, Kim, Won Seog, de la Cruz Vicente, Fátima, Martín García-Sancho, Alejandro, Advani, Ranjana, Roncero Vidal, Jose Maria, de Oña Navarrete, Raquel, Marín-Niebla, Ana, Rodriguez Izquierdo, Antonia, Terol, María José, Domingo-Domenech, Eva, Saunders, Andrew, Bendris, Nawal, Mackey, Julie, Leoni, Mollie, and Foss, Francine

Published
2024
Full Text
View/download PDF

2. The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas

Author

Bhansali, Rahul S., Ellin, Fredrik, Relander, Thomas, Cao, Miao, Li, Wenrui, Long, Qi, Ganesan, Nivetha, Stuver, Robert, Horwitz, Steven M., Wudhikarn, Kitsada, Hwang, Steven R., Bennani, N. Nora, Chavez, Julio, Sokol, Lubomir, Saeed, Hayder, Duan, Frank, Porcu, Pierluigi, Pullarkat, Priyanka, Mehta-Shah, Neha, Zain, Jasmine M., Ruiz, Miguel, Brammer, Jonathan E., Prakash, Rishab, Iyer, Swaminathan P., Olszewski, Adam J., Major, Ajay, Riedell, Peter A., Smith, Sonali M., Goldin, Caroline, Haverkos, Bradley, Hu, Bei, Zhuang, Tony Z., Allen, Pamela B., Toama, Wael, Janakiram, Murali, Brooks, Taylor R., Jagadeesh, Deepa, Hariharan, Nisha, Goodman, Aaron M., Hartman, Gabrielle, Ghione, Paola, Fayyaz, Fatima, Rhodes, Joanna M., Chong, Elise A., Gerson, James N., Landsburg, Daniel J., Nasta, Sunita D., Schuster, Stephen J., Svoboda, Jakub, Jerkeman, Mats, and Barta, Stefan K.

Published
2024
Full Text
View/download PDF

3. Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis

Author

Chavez, Julio C, Grajales, Ariel, Sandoval-Sus, Jose, Turba, Elyce, Nodzon, Lisa, Uriepero-Palma, Angimar, Ammad-Ud-Din, Mohammad, Sahakian, Eva, Komrokji, Rami, Sokol, Lubomir, Locke, Frederick L, Shah, Bijal, Lancet, Jeffrey, Sotomayor, Eduardo M, Kharfan-Dabaja, Mohamed A., Bello, Celeste, and Pinilla-Ibarz, Javier

Published
2024
Full Text
View/download PDF

5. Sézary syndrome originates from heavily mutated hematopoietic progenitors

Author

Harro, Carly M., Sprenger, Kimberly B., Chaurio, Ricardo A., Powers, John J., Innamarato, Patrick, Anadon, Carmen M., Zhang, Yumeng, Biswas, Subir, Mandal, Gunjan, Mine, Jessica A., Cortina, Carla, Nagy, Mate Z., Martin, Alexandra L., Handley, Katelyn F., Borjas, Gustavo J., Chen, Pei-Ling, Pinilla-Ibarz, Javier, Sokol, Lubomir, Yu, Xiaoqing, and Conejo-Garcia, Jose R.

Published
2023
Full Text
View/download PDF

7. Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL

Author

Ruan, Jia, Moskowitz, Alison, Mehta-Shah, Neha, Sokol, Lubomir, Chen, Zhengming, Kotlov, Nikita, Nos, Grigorii, Sorokina, Maria, Maksimov, Vladislav, Sboner, Andrea, Sigouros, Michael, van Besien, Koen, Horwitz, Steven, Rutherford, Sarah C., Mulvey, Erin, Revuelta, Maria V., Xiang, Jenny, Alonso, Alicia, Melnick, Ari, Elemento, Olivier, Inghirami, Giorgio, Leonard, John P., Cerchietti, Leandro, and Martin, Peter

Published
2023
Full Text
View/download PDF

9. Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients

Author

Barilà, Gregorio, Grassi, Angela, Cheon, HeeJin, Teramo, Antonella, Calabretto, Giulia, Chahal, Jasmanet, Vicenzetto, Cristina, Almeida, Julia, Shemo, Bryna C., Shi, Min, Gasparini, Vanessa Rebecca, Munoz-Garcia, Noemi, Pastoret, Cédric, Nakazawa, Hideyuki, Oshimi, Kazuo, Sokol, Lubomir, Ishida, Fumihiro, Lamy, Thierry, Orfao, Alberto, Morice, William G., Loughran, Thomas P., Jr., Semenzato, Gianpietro, and Zambello, Renato

Published
2023
Full Text
View/download PDF

10. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion

Author

Zhang, Yumeng, Nguyen, Lynn, Lu, Chuanyi M., Wang, Endi, Lauw, Marietya I.S., Ball, Somedeb, Dong, Ning, Moscinski, Lynn, Chan, Onyee, Yun, Seongseok, Sallman, David, Sokol, Lubomir, Shah, Bijal, Knepper, Todd, Lancet, Jeffery, Komrokji, Rami, Padron, Eric, Kuykendall, Andrew, and Zhang, Ling

Published
2023
Full Text
View/download PDF

11. Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma

Author

Zhang, Yumeng, Rose, Ashley, Khadka, Sushmita, Cao, Biwei, Eatrides, Jennifer, Saeed, Hayder, Shah, Bijal D., Chavez, Julio, Bello, Celeste, Lazaryan, Aleksandr, Khimani, Farhad, Ibarz, Javier Pinilla, Liu, Hien D., Locke, Frederick L., Jain, Michael D., Zhang, Ling, Kharfan-Dabaja, Mohamed A., Kim, Jongphil, Ayala, Ernesto, Nishihori, Taiga, and Sokol, Lubomir

Published
2024
Full Text
View/download PDF

14. B‐cell maturation antigen expression and clinical features of plasmablastic lymphoma

Author

Dong, Ning, primary, Zhang, Hailing, additional, Song, Jinming, additional, Mammadova, Jamila, additional, Shah, Bijal, additional, Saeed, Hayder, additional, Gaballa, Sameh, additional, Grajales‐Cruz, Ariel, additional, Isenalumhe, Leidy, additional, Bello, Celeste, additional, Sokol, Lubomir, additional, Pinilla, Javier, additional, and Chavez, Julio, additional

Published
2024
Full Text
View/download PDF

19. Non-del(5q) myelodysplastic syndromes–associated loci detected by SNP-array genome-wide association meta-analysis

Author

McGraw, Kathy L., Cheng, Chia-Ho, Chen, Y. Ann, Hou, Hsin-An, Nilsson, Björn, Genovese, Giulio, Cluzeau, Thomas, Pellagatti, Andrea, Przychodzen, Bartlomiej P., Mallo, Mar, Arenillas, Leonor, Mohamedali, Azim, Adès, Lionel, Sallman, David A., Padron, Eric, Sokol, Lubomir, Moreilhon, Chimene, Raynaud, Sophie, Tien, Hwei-Fang, Boultwood, Jacqueline, Ebert, Benjamin L., Sole, Francesc, Fenaux, Pierre, Mufti, Ghulam J., Maciejewski, Jaroslaw P., Kanetsky, Peter A., and List, Alan F.

Published
2019
Full Text
View/download PDF

20. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study

Author

O'Connor, Owen A., Falchi, Lorenzo, Lue, Jennifer K., Marchi, Enrica, Kinahan, Cristina, Sawas, Ahmed, Deng, Changchun, Montanari, Francesca, Amengual, Jennifer E., Kim, Hye A., Rada, Aishling M., Khan, Karen, Jacob, Alice T., Malanga, Michelle, Francescone, Mark M., Nandakumar, Renu, Soderquist, Craig R., Park, David C., Bhagat, Govind, Cheng, Bin, Risueño, Alberto, Menezes, Daniel, Shustov, Andrei R., Sokol, Lubomir, and Scotto, Luigi

Published
2019
Full Text
View/download PDF

21. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.

Author

Zelenetz, Andrew D, Gordon, Leo I, Wierda, William G, Abramson, Jeremy S, Advani, Ranjana H, Andreadis, C Babis, Bartlett, Nancy, Byrd, John C, Czuczman, Myron S, Fayad, Luis E, Fisher, Richard I, Glenn, Martha J, Habermann, Thomas M, Harris, Nancy Lee, Hoppe, Richard T, Horwitz, Steven M, Kelsey, Christopher R, Kim, Youn H, Krivacic, Susan, LaCasce, Ann S, Nademanee, Auayporn, Porcu, Pierluigi, Press, Oliver, Rabinovitch, Rachel, Reddy, Nishitha, Reid, Erin, Saad, Ayman A, Sokol, Lubomir, Swinnen, Lode J, Tsien, Christina, Vose, Julie M, Wilson, Lynn, Yahalom, Joachim, Zafar, Nadeem, Dwyer, Mary, and Sundar, Hema

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Orphan Drug, Hematology, Clinical Research, Rare Diseases, Lymphoma, Cancer, Algorithms, Comorbidity, Disease Management, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm Staging, Prognosis, National comprehension cancer network, Oncology & Carcinogenesis, Oncology and carcinogenesis, Health services and systems
Abstract

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the development of effective chemoimmunotherapy regimens. The recently approved small molecule kinase inhibitors (ibrutinib and idelalisib) are effective treatment options for CLL in elderly patients with decreased tolerance for aggressive regimens and in patients with poor prognostic features who do not benefit from conventional chemoimmunotherapy regimens. This portion of the NCCN Guidelines for Non-Hodgkin's Lymphomas describes the recent specific to the incorporation of recently approved targeted therapies for the management of patients with newly diagnosed and relapsed or refractory CLL/SLL.

Published
2015

34. MPN-521 Somatic Mutational Landscape and Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors Among Patients With Myeloid and Lymphoid Neoplasms With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, FGFR1, JAK2, or FLT3

Author

Zhang, Yumeng, Lu, Chuanyi, Wang, Endi, Nguyen, Lynh, Lauw, Marietya, Ball, Somedeb, Dong, Ning, Moscinski, Lynn, Chan, Onyee, Yun, Seongseok, Sallman, David, Sokol, Lubomir, Shah, Bijal, Knepper, Todd, Lancet, Jeffrey, Komrokji, Rami, Kuykendall, Andrew, Padron, Eric, and Zhang, Ling

Published
2022
Full Text
View/download PDF

35. Non-Hodgkin's lymphomas, version 4.2014.

Author

Zelenetz, Andrew D, Gordon, Leo I, Wierda, William G, Abramson, Jeremy S, Advani, Ranjana H, Andreadis, C Babis, Bartlett, Nancy, Byrd, John C, Czuczman, Myron S, Fayad, Luis E, Fisher, Richard I, Glenn, Martha J, Harris, Nancy Lee, Hoppe, Richard T, Horwitz, Steven M, Kelsey, Christopher R, Kim, Youn H, Krivacic, Susan, LaCasce, Ann S, Nademanee, Auayporn, Porcu, Pierluigi, Press, Oliver, Rabinovitch, Rachel, Reddy, Nishitha, Reid, Erin, Saad, Ayman A, Sokol, Lubomir, Swinnen, Lode J, Tsien, Christina, Vose, Julie M, Yahalom, Joachim, Zafar, Nadeem, Dwyer, Mary, and Sundar, Hema

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Hematology, Rare Diseases, Stem Cell Research, Lymphoma, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Humans, Lymphoma, Non-Hodgkin, Neoplasm Staging, Recurrence, National comprehensive cancer network, Oncology & Carcinogenesis, Oncology and carcinogenesis, Health services and systems
Abstract

Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL cases. Radiation therapy with or without systemic therapy is a reasonable approach for the few patients who present with early-stage disease. Rituximab-based chemoimmunotherapy followed by high-dose therapy and autologous stem cell rescue (HDT/ASCR) is recommended for patients presenting with advanced-stage disease. Induction therapy followed by rituximab maintenance may provide extended disease control for those who are not candidates for HDT/ASCR. Ibrutinib, a Bruton tyrosine kinase inhibitor, was recently approved for the treatment of relapsed or refractory disease. This manuscript discusses the recommendations outlined in the NCCN Guidelines for NHL regarding the diagnosis and management of patients with MCL.

Published
2014

36. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor

Author

Verstovsek, Srdan, Tam, Constantine S, Wadleigh, Martha, Sokol, Lubomir, Smith, Catherine C, Bui, Lynne A, Song, Chunyan, Clary, Douglas O, Olszynski, Patrycja, Cortes, Jorge, Kantarjian, Hagop, and Shah, Neil P

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Hematology, Rare Diseases, Clinical Research, Peripheral Neuropathy, Neurodegenerative, Neurosciences, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Drug Administration Schedule, Drug Monitoring, Early Termination of Clinical Trials, Female, Humans, Janus Kinase 2, Male, Middle Aged, Neurotoxicity Syndromes, Primary Myelofibrosis, Proline, Protein Kinase Inhibitors, Pyrimidines, Myelofibrosis, JAK2, XL019, Mutation, Inhibitor, Immunology, Cardiovascular medicine and haematology
Abstract

This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300 mg orally on days 1-21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21 h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients.

Published
2014

38. Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study

Author

Basiorka, Ashley A, McGraw, Kathy L, Abbas-Aghababazadeh, Farnoosh, McLemore, Amy F, Vincelette, Nicole D, Ward, Grace A, Eksioglu, Erika A, Sallman, David A, Ali, Najla Al, Padron, Eric, Pinilla-Ibarz, Javier, Komrokji, Rami, Masala, Erico, Santini, Valeria, Kosmider, Olivier, Fontenay, Michaela, Fenaux, Pierre, Sokol, Lubomir, Wei, Sheng, Fridley, Brooke, and List, Alan F

Published
2018
Full Text
View/download PDF

39. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma

Author

Yazbeck, Victor, Shafer, Danielle, Perkins, Edward B., Coppola, Domenico, Sokol, Lubomir, Richards, Kristy L., Shea, Thomas, Ruan, Jia, Parekh, Samir, Strair, Roger, Flowers, Christopher, Morgan, David, Kmieciak, Maciej, Bose, Prithviraj, Kimball, Amy, Badros, Ashraf Z., Baz, Rachid, Lin, Hui-Yi, Zhao, Xiuhua, Reich, Richard R., Tombes, Mary Beth, Shrader, Ellen, Sankala, Heidi, Roberts, John D., Sullivan, Daniel, Grant, Steven, and Holkova, Beata

Published
2018
Full Text
View/download PDF

41. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation

Author

Kharfan-Dabaja, Mohamed A., Kumar, Ambuj, Ayala, Ernesto, Hamadani, Mehdi, Reimer, Peter, Gisselbrecht, Christian, d'Amore, Francesco, Jantunen, Esa, Ishida, Takashi, Bazarbachi, Ali, Foss, Francine, Advani, Ranjana, Fenske, Timothy S., Lazarus, Hillard M., Friedberg, Jonathan W., Aljurf, Mahmoud, Sokol, Lubomir, Tobinai, Kensei, Tse, Eric, Burns, Linda J., Chavez, Julio C., Reddy, Nishitha M., Suzuki, Ritsuro, Ahmed, Sairah, Nademanee, Auayporn, Mohty, Mohamad, Gopal, Ajay K., Fanale, Michelle A., Pro, Barbara, Moskowitz, Alison J., Sureda, Anna, Perales, Miguel Angel, Carpenter, Paul A., and Savani, Bipin N.

Published
2017
Full Text
View/download PDF

43. Supplementary Table from Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma

Author

Song, Xiaofei, primary, Chang, Shiun, primary, Seminario-Vidal, Lucia, primary, de Mingo Pulido, Alvaro, primary, Tordesillas, Leticia, primary, Song, Xingzhi, primary, Reed, Rhianna A., primary, Harkins, Andrea, primary, Whiddon, Shannen, primary, Nguyen, Jonathan V., primary, Segura, Carlos Moran, primary, Zhang, Chaomei, primary, Yoder, Sean, primary, Sayegh, Zena, primary, Zhao, Yun, primary, Messina, Jane L., primary, Harro, Carly M., primary, Zhang, Xiaohui, primary, Conejo-Garcia, José R., primary, Berglund, Anders, primary, Sokol, Lubomir, primary, Zhang, Jianhua, primary, Rodriguez, Paulo C., primary, Mulé, James J., primary, Futreal, Andrew P., primary, Tsai, Kenneth Y., primary, and Chen, Pei-Ling, primary

Published
2023
Full Text
View/download PDF

45. Data from Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma

Author

Song, Xiaofei, primary, Chang, Shiun, primary, Seminario-Vidal, Lucia, primary, de Mingo Pulido, Alvaro, primary, Tordesillas, Leticia, primary, Song, Xingzhi, primary, Reed, Rhianna A., primary, Harkins, Andrea, primary, Whiddon, Shannen, primary, Nguyen, Jonathan V., primary, Segura, Carlos Moran, primary, Zhang, Chaomei, primary, Yoder, Sean, primary, Sayegh, Zena, primary, Zhao, Yun, primary, Messina, Jane L., primary, Harro, Carly M., primary, Zhang, Xiaohui, primary, Conejo-Garcia, José R., primary, Berglund, Anders, primary, Sokol, Lubomir, primary, Zhang, Jianhua, primary, Rodriguez, Paulo C., primary, Mulé, James J., primary, Futreal, Andrew P., primary, Tsai, Kenneth Y., primary, and Chen, Pei-Ling, primary

Published
2023
Full Text
View/download PDF

47. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

Author

Trotman, Judith, Joske, David, Prince, H. Miles, Taylor, Kerry, Lewis, Ian D., Jonak, Constanze, Trautinger, Franz, Bechter, Oliver, Wolter, Pascal, Bron, Dominique, de Lima, Vladmir Claudio C., Sanches, Jose Antonio, Junior, Klasa, Richard, Bagot, Martine, Beylot-Barry, Marie, Dalle, Stephane, D'Incan, Michel, Dreno, Brigitte, Grange, Florent, Nicolay, Jan, Stadler, Rudolf, Weichenthal, Michael, Wobser, Marion, Assaf, Chalid, Loquai, Carmen, Quaglino, Pietro, Spina, Michele, Zinzani, Pier Luigi, Bosi, Alberto, Fattori, Pier Paolo, Grzanka, Aleksandra, Walewski, Jan, Lopez-Hernandez, Andres, Ortiz-Romero, Pablo L., Roca, Jose Juan Rifon, Canales, Silvana Novelli, Dummer, Reinhard, Illidge, Timothy, Johnson, Rod, Whittaker, Sean, Morris, Stephen, McKay, Pam, Scarisbrick, Julia, Duvic, Madeleine, Feldman, Tatyana, Akilov, Oleg, Geskin, Larisa, Horwitz, Steve, Kim, Youn H., Pro, Barbara, Kuzel, Timothy, Lerner, Adam, Eradat, Herbert, Sokol, Lubomir, Fisher, David C., Hughey, Sarah, Prince, H Miles, Kim, Youn H, Horwitz, Steven M, Sanches, Jose A, Ortiz-Romero, Pablo L, Akilov, Oleg E, Fisher, David, Dréno, Brigitte, Kuzel, Timothy M, Wang, Yinghui, Palanca-Wessels, Maria Corinna, Zagadailov, Erin, Trepicchio, William L, Zhang, Wenwen, Lin, Hui-Min, Liu, Yi, Huebner, Dirk, and Little, Meredith

Published
2017
Full Text
View/download PDF

50. Figure S1 from A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease

Author

Kurzrock, Razelle, primary, Voorhees, Peter M., primary, Casper, Corey, primary, Furman, Richard R., primary, Fayad, Luis, primary, Lonial, Sagar, primary, Borghaei, Hossein, primary, Jagannath, Sundar, primary, Sokol, Lubomir, primary, Usmani, Saad Z., primary, van de Velde, Helgi, primary, Qin, Xiang, primary, Puchalski, Thomas A., primary, Hall, Brett, primary, Reddy, Manjula, primary, Qi, Ming, primary, and van Rhee, Frits, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results